New drug firsekibart takes on anakinra in Still's disease showdown
NCT ID NCT07191444
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two medications, firsekibart and anakinra, to see which works better and is safer for people with Adult-Onset Still's disease (AOSD). The trial will enroll 20 adults aged 18 to 75 who have been diagnosed with AOSD. The main goal is to see how many patients achieve inactive disease after 24 weeks of treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT ONSET STILL'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200025, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.